ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% in last session and finished the day at $1.41. Traded volume was 1.29million shares in the last session and the average volume of the stock remained 836.94K shares. The beta of the stock remained 1.35. ArQule, Inc. (NASDAQ:ARQL) insider ownership is 0.80%.

The Shareholders Foundation announces that an investor who currently holds shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) filed a lawsuit against the CEO of AVEO Pharmaceuticals, Inc. and seven other officers over alleged breaches of fiduciary duties in connection with AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s drug Tivopath or tivozanib. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) closed to $1.07 Friday on volume of 446,185.00million shares. The intra-day range of the stock was $1.05 to $1.10. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has a market capitalization of $55.93million.

Investment analysts at Guggenheim decreased their price target on shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) from $15.00 to $13.00 in a note issued to investors on Friday, 09 May 2014, AnalystRatings.Net reports. Guggenheim’s target price would suggest a potential upside of 129.68% from the company’s current price. A number of other firms have also recently commented on TLOG. Analysts at WBB Securities upgraded shares of Tetralogic Pharmaceuticals Corp from a “speculative buy” rating to a “buy” rating in a research note on Wednesday, April 9th. They now have a $15.50 price target on the stock, up previously from $12.00.

Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)’s stock on May 23, 2014 reported a decrease of -2.11% to the closing price of $4.17. Its fifty two weeks range is $4.09 -$14.75. The total market capitalization recorded $92.90million. The overall volume in the last trading session was 160,170.00million shares. In its share capital, TLOG has 22.29million outstanding shares.

TrovaGene Inc (TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at TROV given that, according to its RSI reading of 24.68, it is now in oversold territory. On Friday, shares of TrovaGene Inc (NASDAQ:TROV) advanced 0.57% to close the day at $3.55. Company return on investment (ROI) is -50.70% and its monthly performance is recorded as -29.70%. TrovaGene Inc (NASDAQ:TROV) quarterly revenue growth is -45.13%.